Important regulatory notice. Ipamorelin is not licensed by the MHRA for human or veterinary use in the United Kingdom. It is supplied to the laboratory market as a research-use-only reference compound and is prohibited in sport under the WADA Prohibited List as a growth-hormone secretagogue. This page is a literature-context overview and trust-signal sourcing reference. It is not personal-use guidance and Peptides Lab UK does not endorse any human or veterinary use of Ipamorelin.
Quick reference summary. Ipamorelin is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) acting as a selective growth-hormone secretagogue at the GHS-R1a (ghrelin) receptor in the published pharmacology literature. The published research is dominated by in-vitro receptor pharmacology, animal endocrinology models and small early-stage clinical work. Ipamorelin has not progressed through the regulated drug-development pathway to UK marketing authorisation. Peptides Lab UK supplies Ipamorelin as a research-use-only laboratory reference compound with batch-specific HPLC certificates of analysis.
UK regulatory and sport-testing position (2026)
Ipamorelin has no UK marketing authorisation. The MHRA opened investigations in April 2026 into UK clinics making therapeutic claims about unregulated peptide products (reported by The Guardian and the BBC). Ipamorelin is also prohibited in sport under the WADA Prohibited List as a growth-hormone secretagogue. WADA-accredited laboratories run targeted assays for the GHRP and GHS class. Anyone competing under WADA, UK Anti-Doping (UKAD), professional federation rules or military testing should treat Ipamorelin as a detectable banned substance.
What the molecule actually is
Ipamorelin is a synthetic pentapeptide first characterised by Raun and colleagues at Novo Nordisk in the late 1990s as a selective growth-hormone secretagogue at the GHS-R1a (ghrelin) receptor. The selectivity profile reported in the original pharmacology papers describes growth-hormone release with relatively low effect on ACTH, cortisol or prolactin in the experimental systems studied. This is biochemistry described in the published literature, not endorsed clinical outcomes.
What the published research record covers
The peer-reviewed Ipamorelin literature is dominated by in-vitro receptor pharmacology (GHS-R1a binding and signalling), animal endocrinology models, and a small number of human early-stage studies (notably an FDA-stalled trial in postoperative ileus that did not progress to approval). Large blinded placebo-controlled human trials in defined clinical indications are sparse, and Ipamorelin has not progressed to UK marketing authorisation in any indication.
Quality requirements for a research-grade reference sample
For laboratory researchers, identity and purity are the only metrics that matter. A responsible supplier publishes:
- Batch-specific certificate of analysis (COA), downloadable per batch
- Third-party HPLC purity data with chromatogram
- Mass-spectrometry identity confirmation against the Ipamorelin reference standard
- Clear research-use-only labelling, with no human or veterinary use claim
- Stability and storage data for the supplied batch
Peptides Lab UK supplies Ipamorelin on this basis. View our research-grade Ipamorelin listing for batch documentation, packaging and pricing. Researchers studying combined GHRH-and-secretagogue pharmacology can also see the CJC-1295 No DAC and Ipamorelin combined research blend.
How to evaluate any UK Ipamorelin supplier
Five questions to ask any UK supplier before placing a research-grade order. (1) Does each batch ship with a third-party HPLC COA? (2) Is mass-spectrometry identity confirmation available? (3) Is the labelling research-use-only with no human-use claims? (4) Is the supplier transparent about source manufacturing and storage chain? (5) Does the supplier publish stability data for the supplied batch? Any ‘no’ or vague answer is a red flag in the current UK enforcement environment.
Frequently Asked Questions
Is Ipamorelin licensed in the UK?
No. Ipamorelin has no UK, EU or US marketing authorisation in any clinical indication.
Is Ipamorelin banned in sport?
Yes. Ipamorelin is prohibited under the WADA Prohibited List as a growth-hormone secretagogue.
What does the published research record cover?
In-vitro receptor pharmacology at the GHS-R1a (ghrelin) receptor, animal endocrinology models, and a small number of early-stage human studies. Large licensed clinical trials are not part of the public record.
What should a research-grade Ipamorelin reference sample come with?
Batch-specific COA, third-party HPLC purity data, mass-spectrometry identity confirmation, clear research-use-only labelling, and stability documentation.
Where can I read the source literature?
The peer-reviewed Ipamorelin literature is indexed on PubMed. The Raun et al. 1998 Novo Nordisk papers are the foundational reference.
Research use only. Peptides Lab UK supplies research-use-only laboratory reference compounds with batch-specific certificates of analysis. Products are not for human or veterinary use. Ipamorelin is also banned in sport under the WADA Prohibited List.
